Get the Stockscreener App
362.78
0.75%
2.78
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Cencora Inc stock is traded at $362.78, with a volume of 317.96K.
It is up +0.75% in the last 24 hours and up +8.05% over the past month.
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
See More
Previous Close:
$360.00
Open:
$360.46
24h Volume:
317.96K
Relative Volume:
0.23
Market Cap:
$70.59B
Revenue:
$325.78B
Net Income/Loss:
$1.64B
P/E Ratio:
43.64
EPS:
8.3139
Net Cash Flow:
$3.61B
1W Performance:
+9.92%
1M Performance:
+8.05%
6M Performance:
+24.77%
1Y Performance:
+46.99%
1-Day Range:
$358.29
$363.06
1-Week Range:
$332.99
$367.28
52-Week Range:
$237.71
$377.54
Cencora Inc Stock (COR) Company Profile
Name
Cencora Inc
Sector
Industry
Phone
610-727-7000
Address
1 WEST FIRST AVENUE, CONSHOHOCKEN
Compare COR vs MCK, CAH, HSIC, AHG
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COR
Cencora Inc
|
362.86 | 70.03B | 325.78B | 1.64B | 3.61B | 8.3139 |
|
MCK
Mckesson Corporation
|
940.76 | 114.55B | 397.96B | 4.55B | 9.64B | 34.77 |
|
CAH
Cardinal Health Inc
|
224.00 | 51.83B | 244.67B | 1.68B | 5.51B | 6.9487 |
|
HSIC
Henry Schein Inc
|
81.07 | 9.54B | 12.50B | 314.00M | 421.00M | 2.44 |
|
AHG
Akso Health Group Adr
|
1.41 | 793.60M | 2.22M | -5.63M | -1.68M | -0.24 |
Cencora Inc Stock (COR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-26 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-22-26 | Upgrade | Jefferies | Hold → Buy |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Jun-03-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-04-24 | Resumed | Mizuho | Outperform |
| Sep-18-24 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Jan-03-24 | Initiated | Barclays | Overweight |
| Dec-14-23 | Initiated | Wells Fargo | Equal Weight |
| Mar-31-23 | Initiated | Citigroup | Buy |
| Jan-31-23 | Resumed | Evercore ISI | Outperform |
| Oct-11-22 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-22-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-11-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Jun-07-22 | Upgrade | Deutsche Bank | Hold → Buy |
| May-26-22 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-12-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Mar-12-21 | Resumed | Evercore ISI | In-line |
| Feb-04-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-02-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-06-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-10-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Dec-03-20 | Initiated | Mizuho | Neutral |
| Aug-06-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-15-20 | Initiated | Barclays | Underweight |
| Jun-15-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-23-20 | Resumed | Credit Suisse | Outperform |
| Apr-16-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-13-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-01-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-17-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-11-20 | Downgrade | BofA/Merrill | Buy → Underperform |
| Feb-07-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-12-19 | Initiated | Deutsche Bank | Hold |
| Jul-10-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Apr-11-19 | Initiated | Guggenheim | Buy |
| Apr-10-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| Apr-10-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-11-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-17-19 | Initiated | UBS | Buy |
| Dec-10-18 | Downgrade | Jefferies | Buy → Hold |
| Oct-26-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-20-18 | Initiated | Berenberg | Buy |
| Jul-17-18 | Resumed | Stifel | Hold |
| Apr-09-18 | Initiated | MoffettNathanson | Buy |
| Mar-12-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
| Mar-12-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-25-17 | Initiated | JP Morgan | Neutral |
| Sep-22-17 | Initiated | William Blair | Outperform |
View All
Cencora Inc Stock (COR) Latest News
Ex-Dividend Reminder: Cencora, Amgen and Oppenheimer Holdings - Nasdaq
5 Revealing Analyst Questions From Cencora's Q4 Earnings Call - Finviz
Versor Investments LP Makes New Investment in Cencora, Inc. $COR - MarketBeat
ING Groep NV Boosts Stake in Cencora, Inc. $COR - MarketBeat
How Investors Are Reacting To Cencora (COR) US$3 Billion Senior Notes To Term Out Acquisition Debt - simplywall.st
Cencora prices $3 billion in senior notes across multiple maturities By Investing.com - Investing.com Nigeria
What are Wall Street analysts' target price for Cencora stock? - MSN
Cencora Prices Senior Notes - marketscreener.com
Cencora prices $3 billion in senior notes across multiple maturities - Investing.com
Cencora prices five bond issues to repay OneOncology acquisition credit - Stock Titan
Cencora (COR) Receives Analyst Rating Update from JP Morgan | CO - GuruFocus
Beyond The Numbers: 6 Analysts Discuss Cencora Stock - Benzinga
Cencora files for five-part senior notes offering size not diclosed - marketscreener.com
Wells Fargo Raises Price Target on Cencora (COR) to $429.00 | CO - GuruFocus
Cencora, Inc. (COR) Announces Strategic Reorganization of Busine - GuruFocus
Cencora Updates Segment Reporting Following Strategic Business Review - TipRanks
Cencora, Inc Revises Financial Reporting Structure - TradingView
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Johnson Investment Counsel Inc. Sells 11,354 Shares of Cencora, Inc. $COR - MarketBeat
Chief Executives for Corporate Purpose Announces Covista Chairman and CEO Steve Beard, Cencora Inc. Former Executive Chair Steven H. Collis, and Ann Fairchild, interim President and CEO of Siemens USA Joining Board of Directors - Yahoo Finance
Is It Too Late To Consider Cencora (COR) After A 46% One-Year Rally? - Yahoo Finance
Envestnet Asset Management Inc. Lowers Stock Holdings in Cencora, Inc. $COR - MarketBeat
Aurdan Capital Management LLC Sells 4,004 Shares of Cencora, Inc. $COR - MarketBeat
Cencora (COR) Valuation Check After Recent Share Price Momentum And Intrinsic Value Discount - simplywall.st
Cencora (COR) Stock Trades Up, Here Is Why - Finviz
Cencora Inc (COR) Trading Down 0% on Feb 5 - GuruFocus
Cencora Lifts 2026 Sales Outlook Despite Q1 Revenue Miss - Sahm
Cencora Q1 2026 Earnings: Profit Exceeds Expectations, Revenue at $85.93BNews and Statistics - IndexBox
Cencora, Inc. $COR Shares Sold by Triglav Investments D.O.O. - MarketBeat
COR Q4 Deep Dive: Specialty Expansion and OneOncology Drive Strategic Shifts - Finviz
BI Asset Management Fondsmaeglerselskab A S Raises Holdings in Cencora, Inc. $COR - MarketBeat
16,364 Shares in Cencora, Inc. $COR Purchased by ABN AMRO Bank N.V. - MarketBeat
Cencora, Inc. (COR) Shares Slide as Revenue Miss Offsets Raised Operating Guidance - AlphaStreet News
Decoding Cencora Inc (COR): A Strategic SWOT Insight - GuruFocus
Cencora Q1 Earnings Call Highlights - Yahoo Finance
Jefferies reiterates Buy rating on Cencora stock, sees upside potential By Investing.com - Investing.com Australia
Cencora (COR) Margin Stays Near 0.5% As High P/E Tests Bullish Growth Narratives - simplywall.st
Cencora Earnings Call: Specialty Strength, Guidance Raised - TipRanks
Cencora Q1 2026 presentation: EPS beat overshadowed by revenue miss and stock drop - Investing.com Nigeria
Cencora Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Cencora Inc (COR) Q1 2026 Earnings Call Highlights: Strong US Gr - GuruFocus
Cencora Inc (COR) Q1 2026 Earnings Call Highlights: Strong US Growth Amid International Challenges By GuruFocus - Investing.com Canada
Jefferies reiterates Buy rating on Cencora stock, sees upside potential - Investing.com
Cencora, Inc. SEC 10-Q Report - TradingView
Leerink reiterates Outperform rating on Cencora stock, citing durable growth By Investing.com - Investing.com Canada
Leerink reiterates Outperform rating on Cencora stock, citing durable growth - Investing.com
Cencora Well-Positioned for Durable Long-Term Growth From Strong Demand and Specialty Investments - Morningstar
Cencora, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2025 - marketscreener.com
Cencora Stock Down Despite Q1 Earnings Beat, Gross Margin Improves - Yahoo Finance
Cencora Lifts 2026 Sales Outlook Despite Q1 Revenue Miss - Benzinga
Cencora beats quarterly profit estimates on strong demand for specialty medicines - marketscreener.com
Cencora Inc Stock (COR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
2.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):